SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Sunesis Pharmaceuticals (SNSS)
An SI Board Since November 2005
Posts SubjectMarks Bans Symbol
48 10 0 SNSS
Emcee:  John McCarthy Type:  Unmoderated
Introduction Market Data Compact
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
23How does everyone feel about SNSS these days? I bought this close to $5 before mcbio-3/7/2008
22>>Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and tuck-8/28/2007
21Anyone has a clue about the drop on large vol? If this is not a leak of bad newsidos-6/26/2007
20Never held any, but they're on my list, too.nigel bates-2/5/2007
19Nigel, this company has been on my 'to watch' radar since I assigned myszeta1961-1/29/2007
18Sunesis Pharmaceuticals Reports Positive Initial Results From Phase 2 Small Cellnigel bates-1/29/2007
17Sunesis Out-Licenses LFA-1 Program to SARcode Corporation Thursday January 4, 8:nigel bates-1/4/2007
16Interesting, because the same investigator did the KOS-1022 trial in about the stuck-12/11/2006
15Preliminary Results from Sunesis Pharmaceuticals' Phase 1 Trial of SNS-595 inigel bates-12/10/2006
14Sunesis Pharmaceuticals Announces Preclinical Milestone Payment in BACE Collabornigel bates-6/12/2006
13Sunesis Pharmaceuticals Initiates Phase II Clinical Trial of SNS-595 in Small Cenigel bates-3/20/2006
12Sunesis Pharmaceuticals Initiates Phase II Clinical Trial of SNS-595 in Non-Smalnigel bates-1/4/2006
11Sunesis Pharmaceuticals Receives Milestone Payment from Biogen Idec SOUTH John McCarthy-12/7/2005
10<<The abstract says the G2 phase, the PR says the S phase>> <i>tnsaf-11/17/2005
9>>PHILADELPHIA, Nov. 17 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals,tuck-11/17/2005
8Sunesis Pharmaceuticals Initiates Leukemia Clinical Trial Tuesday November 15, 8John McCarthy-11/15/2005
7Sunesis Pharmaceuticals Reports Third Quarter 2005 Financial Results SOUTHJohn McCarthy-11/14/2005
6Sunesis Pharmaceuticals to Report Third Quarter Financial Results on November 1John McCarthy-11/9/2005
5Abstract Phase I trial of SNS-595 in patients with advanced malignancies R. AJohn McCarthy-11/7/2005
4Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment oJohn McCarthy-11/7/2005
3Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the TJohn McCarthy-11/7/2005
2Sunesis Presents Data on Anti-Cancer Therapy, SNS-595 at American Association ofJohn McCarthy-11/7/2005
1Sunesis Pharmaceuticals to Present Data on SNS-595 and Kinase Inhibitor ProgramsJohn McCarthy-11/7/2005
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News